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Abstract
Cytosine methylation provides an epigenetic level of cellular plasticity that is important for development, differentiation and
cancerogenesis. We adopted microdroplet PCR to bisulfite treated target DNA in combination with second generation
sequencing to simultaneously assess DNA sequence and methylation. We show measurement of methylation status in a
wide range of target sequences (total 34 kb) with an average coverage of 95% (median 100%) and good correlation to the
opposite strand (rho=0.96) and to pyrosequencing (rho=0.87). Data from lymphoma and colorectal cancer samples for
SNRPN (imprinted gene), FGF6 (demethylated in the cancer samples) and HS3ST2 (methylated in the cancer samples) serve
as a proof of principle showing the integration of SNP data and phased DNA-methylation information into ‘‘hepitypes’’ and
thus the analysis of DNA methylation phylogeny in the somatic evolution of cancer.
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Introduction
Epigenetic mechanisms are key to the control of local tran-
scriptional activity [1]. Methylation of cytosine residues at the
carbon 5 position (5
meC) in the context of CpG motifs is one of the
best studied epigenetic marks. DNA methylation in mammalian
genomes can affect different genomic areas, such as repeat regions,
gene promoters and the gene body. Whereas methylation of DNA
repeats is assumed to regulate genome stability, DNA methylation
of CpG islands in gene promoters and the gene proper have been
inversely linked to gene expression [2,3].
Alterations in DNA methylation are not only crucial for normal
development but are also characteristic of several physiologic and
disease associated mechanisms, including ageing, imprinting
defects and genomic instability syndromes [4]. Altered DNA
methylation patterns have been particularly well studied in cancer
[5,6,7]. Virtually all cancers are in some way associated with
aberrant DNA methylation. High levels of DNA methylation at
gene promoter regions have been described in hematologic
neoplasms like germinal-center B-cell derived lymphomas and in
solid tumors like colorectal, prostate and brain cancer [8,9,10].
Initially, altered methylation has been assumed to be one of the
key silencing mechanisms for tumor-suppressor-like genes [11].
Nevertheless, increasing evidence suggests that in cancer DNA-
methylation is a phenomenon encompassing a wide array of gene
types [10,12]. Remarkably, among methylation targets in various
types of cancer, target genes of the polycomb repressive complexes
(PRC1 and PRC2) in stem cells are strongly enriched. These genes
regulate key developmental processes and play an important role
in differentiation and the maintenance of cell fates [13,14,15].
Polycomb target gene methylation has been reported as a specific
pattern of de novo methylation in cancer [16,17], although the
stability and mechanistic interaction of this gene set in evolving
cancer cells remains to be clarified [18].
Whereas much is known about the somatic patterns of DNA
methylation in cancer only scarce data exist that link genetic (e.g.
DNA based) predisposition to cancer to the somatic manifestation
of clonal outgrowth. Given that many predisposing loci are
associated with a restricted spectrum of cancers, it is intriguing to
speculate that epigenetic factors are involved in the somatic
manifestation of disease predisposition. This concept recently leads
to the definition of ‘‘hepitypes’’, i.e. the description of (DNA-
based) haplotypes which change the local epigenetic landscape
[19,20,21]. The analysis of such hepitypes may provide an in-
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analysis of both sequence variation and differential DNA methy-
lation [3]. This is especially important in the context of the many
large regions identified as polygenic risk factors for cancers such as
colorectal, breast and prostate cancer through recent genome-wide
association studies [22]. Ideally a parallel, deep analysis of soma-
tic variation and methylation over continuous stretches of DNA
should be conducted in order to understand the interaction of
germline risk factors, somatic genetic and epigenetic evolution
within the tumor [23,24], not the least because altered methylation
may affect cytosine residues outside a CpG context [25].
A number of methodologies for the analysis of methylation in
the human genome are available including assays based on enzy-
matic digestion, affinity enrichment and sodium bisulfite enrich-
ment, which have been recently reviewed [26,27,28]. Although a
number of methods have been developed in order to increase
throughput and ease of methylation analysis, no universally appli-
cable technology has emerged as of yet. One possible approach
uses bisulfite conversion; i.e. treatment of genomic DNA with
sodium bisulfite (BS) to convert cytosine, but not methylcytosine,
to uracil, and subsequent sequencing. Single-base methylation
analysis was previously achieved using this method for proportions
of the human genome [29,30] and on a whole-genome level in
Arabidopsis thaliana [31] and recently also in mammalian cells
[25]. While these studies demonstrated the applicability of BS
sequencing on the whole-genome level, some drawbacks including
the cost of sequencing and bioinformatic alignment remain. Cost
and coverage are particularly important if a quantitative assess-
ment of the relative methylation of individual sites in a multiclonal
tumor sample is attempted. We have thus adapted the recently
described microdroplet PCR [32] to BS treated target DNA and
established a pipeline for the simultaneous assessment of DNA
sequence analysis and methylation and demonstrate the practical
applicability using samples from colon cancer and follicular
lymphomas.
Methods
Primer design pipeline for bisulfite-converted target DNA
Target regions for the methylation analysis with a total of 34083
base pairs of sequence were selected as detailed in Table S1.
Forward and reverse strands of the target sequence were bisulfite
converted in silico. The converted DNA was fragmented in silico
into 200, 300 or 400 bp segments using a spacing of 5 bp. These
segments were submitted to Primer3 [33] using the following
parameters: target primer melting temperature 5662uC, maximal
difference between primer melting temperature 2uC, optimal
primer size 20 bp [min=18, max=25], optimal GC content 60uC
[min=20uC, max=90uC] and amplicon range search segment
size 650 bp. For each sequence segment, the five best primer pairs
based on the Primer3 quality score were selected. In order to
minimize allelic amplification bias, primers covering the location
of a HapMap annotated SNP with a minor allele frequency .0.1
or a CpG island were removed. Redundant primer pairs were
eliminated and the remaining primers checked by e-PCR [34]
against the whole bisulfite converted genome. All primer pairs
yielding off-target products of up to 2 kb were filtered out. Using a
target coverage of 2-fold for the 300 bp design and a 3-fold
coverage for the 200 bp and 400 bp amplicon design, primers
were each selected by increasing GC-content to the desired
coverage. For regions, where the above described criteria failed to
produce the target coverage, the melting temperature criteria were
relaxed to 5666uC and the procedure repeated. A list of all primer
pairs and their normalized sequencing yield is provided in Table
S2, thus providing an indication of efficiency for each PCR and
sequencing reaction.
Design pipeline for non-converted DNA
Chromosomal coordinates (NCBI build 36/hg18) for the target
regions were submitted to the RainDance Technologies primer
design pipeline as described [32]. In brief, PCR primer pairs were
designed for the target regions using a Primer3-based algorithm
[33]. Known SNPs were masked prior to PCR primer design
(dbSNP 129). PCR primers were designed to have a melting
temperature (Tm)o f5 8 uC61uC with an optimal length of 20 bases
and an upper amplicon size of 600 base pairs. For target regions
which were greater than 600 bp or for which a single amplicon
of 600 bp was not able to be designed within parameters, an
amplicon tiling strategy was used to cover the region. All PCR
primer pairs were checked by in silico PCR [35] to identify regions
of the genome other than the intended target region which could
potentially be amplified. A total of 249 PCR primer pairs were
designed that covered the entire 58716 bp of the target region
and thus slightly more sequence than the converted design. All
CpGs that are created through allelic variation in the samples are
marked separately in Table S3. An overview of all variants
detected in this study is provided in Table S4.
Samples and bisulfite conversion
For the proof of principle experiments, DNA was prepared from
tumor (CRC-TU) and normal tissue (CRC-NT) in a 65 year old
male colon cancer patient. The cancer showed no evidence of
microsatellite instability. In addition, we studied two lymph node
specimens of a female patient initially diagnosed at age 60 years
with follicular lymphoma (FL) stage IV with bone marrow involve-
ment [36]. The specimens analyzed were diagnosed with typical
FL1/2 obtained at relapse after partial remission achieved with
anthracycline-containing chemotherapy one (FL-R1) and four
(FL-R2) years after initial diagnosis. The FL hallmark transloca-
tion t(14;18)(q32;q21) was detected by FISH using the LSI IGH/
BCL2 probe (Abbott) in 39% and 84% of nuclei in the both
samples, respectively. Breakpoints affecting the BCL6 and MYC
loci as well as IGH-MYC fusion were absent in both specimens by
interphase FISH using commercially available probes (LSI BCL6
BAP, LSI MYC BAP, LSI IGH/MYC all of Abbott). Lymphoma
cells expressed CD20, CD10, BCL2 and BCL6 in accordance with
the diagnosis.Tissues samples were used in accordance with the
protocols of the Colon Cancer Network and Ha ¨matoSys Networks
for which IRB approval of the Ethics Committee of the Medical
Faculty of the Christian-Albrechts-University Kiel was obtained.
All sample DNAs were bisulfite converted using the EpiTect
Bisulfite Kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s instructions. A verification of successful bisulfite conver-
sion is shown in Figure S1.
Droplet PCR and Optimization
PCR primers designed to amplify the desired target regions
from bisulfite treated DNA were synthesized, emulsified into a
primer droplet library and merged with the target DNA of interest
on the RDT 1000 instrument (RainDance Technologies, Lex-
ington, MA/USA) as described [32]. In order to optimize both
template buffer conditions and PCR cycling conditions, several
sequence enrichment merges were performed varying both the
MgSO4 concentrations and the annealing temperature. Following
amplification and breaking of the emulsion, the sequence enriched
amplicons were purified over a Qiagen MinElute column (Qiagen
AG, Hilden, Germany) and eluted in 11 mL of EB buffer from the
Qiagen kit. One mL of the eluted amplicons was run on an Agilent
Pipeline for Microdroplet Bisulfite PCR Sequencing
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annealing temperature and MgSO4 concentration was determined
by comparing the relative amplicon yields between samples at
different annealing temperatures and MgSO4 concentrations and
by the amount of background noise generated by comparing the
actual Agilent Bioanalyzer profiles to the calculated peak profile.
The calculated peak profile is a graphical representation of the
expected shape of the Agilent Bioanalyzer peak profile created by
generating a histogram from the known amplicon sizes and
numbers (Figure 1, Panel A). The shape of the peak profile
represents what the Agilent Bioanalyzer profile should look like if
all amplicons designed are present at equimolar concentrations
Figure 1 shows both the calculated peak profile (Panel A) and the
actual Agilent Bioanalyzer traces for the merged samples run at
different annealing temperatures (Panel B). At an annealing
temperature of 50uC, the expected amplicon profile is present,
however, there is a large amount of background noise present
presumably due to off target amplification products at this lower
annealing temperature. As the annealing temperature is increased,
the background noise is decreased until it disappears at an an-
nealing temperature of 56uC. Increasing the temperature to 58uC
only decreases the amplicon yield from 307 ng to 215 ng without
changing the background noise. Using this data an annealing
temperature of 56uC was selected. The same procedure was used
to determine the optimal MgSO4 concentration by keeping the
annealing temperature constant at 56uC and varying the MgSO4
concentration from 1.8 mM to 2.5 mM (data not shown). Using
this method it was determined that the optimal MgSO4 con-
centration for PCR amplification at an annealing temperature of
56uCfor this primer droplet library was 2.5 mM.
Library sequencing
Sequencing libraries were prepared according to Roche’s rapid
library preparation method manual (Roche, Hartford, CT/USA,
release October 2009) with the following modifications: 134–
288 ng of non-converted or bisulfite-converted micro droplet
PCR products were used as starting material. The samples were
directly subjected to fragment end repair (step 3.2) without prior
nebulisation. Roche’s MID-containing rapid-adapters were
ligated to the samples. The fragment removal step (step 3.5)
was replaced by purification with AmPure beads in order to
remove excess adaptors but to retain the smaller RainDance
products. The sample volume was adjusted to 50 ml with EB-
Buffer (Qiagen) and the sample was added to 90 ml of AmPure
XP beads (Agencourt Biosciences, Beverly, MA/USA). The
sample was vortexed and incubated for 5 min at room tem-
perature. The tube was placed for 3 min on a magnetic particle
concentrator to pellet the beads. The supernatant was removed
and the beads were washed two times with 500 ml 70% ethanol.
Residual ethanol was removed by incubation at 37uC for 15 min.
The purified sample was eluted with 50 ml TE-Buffer. Rapid
libraries were quantified and diluted according to the rapid
library protocol. Equal quantities of the non-bisulfite-converted
samples were pooled. Titrations of the single bisulfite-converted
libraries and the pooled non-bisulfite-converted libraries were
performed according to Roche’s emPCR method manual-Lib-L
SV (October 2009). For the final bead enrichment (according to
Roche’s emPCR method manual-Lib-L LV, October 2009) a
copy-per-bead ratio of 0.5 was used for the bisulfite-converted
libraries and a copy-per-bead ratio of 1.5 was employed for the
non-bisulfite-converted pool yielding enrichment rates between
7% and 12%. For each bisulfite-converted library and the pool of
non-bisulfite-converted libraries a full sequencing run was per-
formed according to Roche’s protocol (Sequencing Method
Manual, October 2009). Since reads from the non-bisulfite
converted sample FL-R2 were underrepresented, sequencing of
this library was repeated individually on 1/2 sequencing plate.
Read data was extracted using the shotgun setting of the Roche
analysis module.
Analysis Pipeline
The data from the unconverted libraries were analysed as
described previously [32]. The sequence reads from the converted
libraries were compared to the total primer library using the
string-search algorithm suggested by Ukkonen [37] allowing for
a maximum of two differences per primer. Sequences without
matches in the primer library, accounting for approximately 5% of
reads, were eliminated. Subsequently, each sequence read was
aligned to all potential amplicons compatible with the primer
sequences using a modified dynamic programming alignment
algorithm [38]. All sequence reads yielding a minimum of 50
matching bases and greater than 95% sequence identity to a target
amplicon were selected for further analysis. This criterion was
chosen in accordance to previous publications [38] to allow for
variation (i.e. the 95% identity criterion to allow for differential
methylation or SNPs) by requiring a minimum matching sequence
length to assure the amplicon assignment. We frequency of mis-
matches to the predicted converted and unconverted amplicon
sequence is depicted in Figure S2. It is evident, that the 95%
criterion used typically in SNP discovery experiments is suitable
for the converted amplicon reads as well. Using this filter criterion,
a further 30–40% of reads were eliminated. Ambiguous reads
mapping to different regions of the target sequence were filtered
out, too. Primer sequences were removed before methylation
scoring. Cytosine methylation in the mapped reads was assessed as
the ratio of C to T in the aligned sequences. An overview of the
raw sequence reads and the proportion used for final analysis is
provided in Table 1. The software and example datasets are
available for anonymous download at (http://gengastro.1med.
uni-kiel.de/suppl/methyl454/).
Analysis of methylation using bisulfite pyrosequencing
Analysis of methylation was performed via bisulfite pyrose-
quencing as described previously [8,39]. Primers were designed
using the PyroMark Assay Design Software (Version 2.0). The
amplification reaction was performed using the PyroMark PCR
Kit (Qiagen, Hilden, Germany) according to the manufactures
instructions.
Hepitypes and tree analysis
For each locus of interest only continuous sequence reads
covering the region of interest were considered. Only hepitypes
with a frequency above 1% frequency in the observed reads for a
given sample were considered. Phylogenetic trees were fitted using
unrooted maximum-parsimony methods as implemented in Phylip
3.69 (http://evolution.gs.washington.edu/phylip.html) with de-
fault parameters. Reproducibility of the phylogenetic trees was
assessed using 1000 bootstrap samples. To investigate the hypo-
thesis that single unmethylated sites occur on the background of
all-C hepitypesat the same frequency as single methylated sites do
on the background of all-unmethylated hepitypes, a 262 count
table of deviating sites was constructed. To this end, counts of
methylated/unmethylated hepitypes without any deviating site
formed the first column, whereas hepitype counts with at least one
site deviating from the all-methylated/all-unmethylated back-
ground entered the second column. Fisher’s exact test was then
performed on this 262 table.
Pipeline for Microdroplet Bisulfite PCR Sequencing
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Yield and coverage of target regions
We established a pipeline allowing a simultaneous, targeted
assessment of DNA sequence variation and methylation. This
pipeline is described graphically in Figure 2. For the predeter-
mined genomic regions of interest, primers for microdroplet
amplification of unconverted and BS treated DNA are generated,
the primers libraries are synthetized and PCR conditions
optimized for maximal product yield. The removal of SNP sites
in the primer sequences did not prove to be a critical restriction,
than hindered successful primer design in the target regions
chosen. The results of this optimization of PCR amplification
conditions are depicted in Figure 1 for the 994 primer pairs
covering 34083 bases of genomic sequence excluding primer
sequences. 946 primer pairs were designed using the automated
pipeline for the BS converted DNA. These primers designed
redundantly, so as to provide a target coverage of 8-fold over the
Figure 1. Annealing temperature optimization of the primer droplet library. Panel A – The calculated peak profile created by generating a
histogram of the known amplicon sizes and numbers and assuming equal representation of all the amplicons after PCR amplification. Panel B – The
Agilent Bioanalyzer traces of merged samples PCR amplified with different annealing temperatures. The amplicon peaks and background noise are
highlighted for the 50uC annealing temperature. Background noise decreases until it disappears at 56uC. Increasing the annealing temperature to
58uC only results in a decrease in amplicon yield.
doi:10.1371/journal.pone.0021332.g001
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lished and manually designed primer pairs for CpG islands and a
control plasmid were included in the primer library [8]. The
theoretical distribution of PCR products is depicted in Panel A of
Figure 1. After performing droplet PCR on BS treated DNA as
described in the Methods section, the size distribution of am-
plicons resembled the calculated distribution which is a first
indication of a successful design (Figure 1, Panel B). After micro-
droplet PCR and FLX sequencing of the resulting PCR product
library, the sequence reads were aligned to the converted genome
as described in the Methods. Using the presence of at least one
read of successfully aligned sequence as a criterion, the design
success of the automated pipeline averaged at 95% (median
100%). Less than 0.02% of this sequence was covered by less than
20 aligned reads – the corresponding CpG sites are marked in
italics in Table S3. Out of the 993 primer pairs targeting the
converted human genome in the library, all primers yielded a
product, although some sequences cannot be uniquely assigned to
one primer pair because of the highly redundant design. Thus,
regions not covered in the automated pipeline are due to the
failure to design primers for this proportion of the target sequence,
rather than experimental lack of amplicons for the designed
primers. The one control primer pair for plasmid DNA did not
yield a product in any sample.
A graphical account of the designed primers for the one of the
two largest regions with the lower coverage (IRF4) is given in
Figure 3. Details of the regions and the design and sequencing
success of are provided in Tables S1 and 1. The average coverage
of the non-converted library was 99.7% (median 100%).
Technical reproducibility of the levels of DNA
methylation
For 248 CpG sites from 16 loci both BS sequencing data using
the author’s pipeline and BS pyrosequencing data using con-
ventionally designed control assays (Table S5) were available for
comparison. Overall, the degree of methylation as determined by
the droplet BS PCR pipeline and by BS pyrosequencing was very
similar (Figure 4, Panel A), yielding an overall pairwise Spearman
correlation coefficient of 0.87. For the IGF2 locus (see Table S1 for
coordinates), methylation information from the forward and
reverse strand of all CpG sites was available from the PCR pro-
duct sequencing and pyrosequencing assays. Interestingly, the
cross-stand reproducibility of the droplet PCR sequencing pipeline
was considerably higher than for the pyrosequencing assays, as
reflected by the pairwise correlation coefficients of 0.96 and 0.88,
Table 1. Overview of the samples and reads from the libraries.
Sample Tissue bisulfite reads Total sequence (bp) Mapped reads Mapped bp w/o primers
CRC-NT colon YES 302,893 57,977,571 163,971 30,388,486
CRC-TU colon YES 193,150 39,029,236 119,666 22,368,077
FL-R1 lymphatic YES 857,952 186,092,051 681,836 133,755,191
FL-R2 lymphatic YES 843,643 165,164,339 580,212 105,088,308
CRC-NT colon NO 152,873 61,380,483 127,151 48,206,498
CRC-TU colon NO 183,423 73,311,754 153,450 57,586,858
FL-R1 lymphatic NO 167,205 66,481,618 140,562 52,358,040
FL-R2 lymphatic NO 323,993 109,867,968 223,888 76,258,994
The table gives an overview of the samples and reads obtained from the converted (marked as bisulfite ‘‘YES’’) and unconverted libraries (marked as bisulfite ‘‘NO’’). The
raw number of sequence reads, the number of mapped reads per sample and total analysed sequence after deletion of primer sequences are listed.
doi:10.1371/journal.pone.0021332.t001
Figure 2. The Figure provides a flow chart of the pipeline for
integrated analysis of DNA variation and methylation analysis
as described in this manuscript. The standard design pipeline for
unconverted DNA [32] is marked with an asterisk (*).
doi:10.1371/journal.pone.0021332.g002
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using primers designed specifically for the opposite strands of the
converted DNA.
Analysis of DNA methylation and methylation haplotypes
(‘‘hepitypes’’) in tumors
A total of 2017 differentially methylated CpG sites were
analyzed in this study. Table S3 provides the detailed, per site
methylation information for all four samples investigated. Sites
that were present due to particular SNP alleles could be readily
identified using the data from the non-converted library and are
annotated in Table S3, too.
The readout of the PCR products yielded an average read
length of 204 bases. Owing to these relatively long stretches of
continuous DNA sequence, an analysis of phased methylation
information was possible. We denote the underlying methylation
pattern of these phased sequence reads of converted DNA as
‘‘hepitypes’’ [19,28]. As exemplary loci to demonstrate the fea-
sibility and potential of this experimental approach, the SNRPN
(small nuclear ribonucleoprotein polypeptide N), FGF6 (fibroblast
growth factor 6) and HS3ST2 (heparan sulfate 3-O-sulfotransferase
2) loci were evaluated considering phased methylation covered by
complete physical sequence reads. A minimum hepitype frequency
of 1% was required for analysis.
SNRPN (small nuclear ribonucleoprotein polypeptide N)
SNRPN was investigated as an example of an imprinted gene,
i.e. a gene differentially methylated on and expressed from the two
parental alleles. The SNRPN gene (OMIM 182279) is transcribed
exclusively from the paternally inherited chromosome. SNRPN is
located within an imprinted gene cluster in chromosome 15 that is
associated with Prader-Willi syndrome (PWS; OMIM 176270) and
Angelman syndrome (OMIM 105830) [40]. PWS arises from loss
of gene function in this region, expressed exclusively from the
paternal chromosome; this suggests that SNRPN may play a role
in its etiology. Theoretically, given the equal distribution of both
parental alleles in a healthy tissue sample, one would expect 50%
of all alleles in such a sample to be methylated and 50% to be
unmethylated. As shown in Figure 5, the completely unmethylated
hepitype and completely methylated locus comprised 55% and
39% of all sequence reads in the studied normal colonic sample
(CRC-NT), respectively. Data for all three other samples are
almost identical (data not shown). Whereas a dichotomy of hepi-
types, reflected in the parsimony tree in Panel B, is expected under
the differential methylation of both alleles, the higher diversity of
the methylated rather than the unmethylated hepitype caused by
incomplete methylation of the supposedly methylated allele is
intriguing. Upon formal analysis of the hepitype data, single
unmethylated sites on the background of the completely methy-
lated hepitype are more common when contrasted with single
methylated sites on the background of the completely unmethy-
lated hepitype not only in the normal sample (CRC-NT, p,
1.0610
215) but also in all the three tumor samples (all p-values
,1.0610
215). This observation is graphically depicted in the
histogram plotting the frequency of additional methylated or
demethylated sites on the respective hepitype background in
Panel C of Figure 5. Overall, these findings of the in-depth BS
sequencing analysis of this imprinted locus using our novel pipeline
might suggest that the active DNA-methyl transferase (DNMT)
driven process of DNA methylation maintenance might be prone
to mistakes in somatic cells. Similar data were obtained for a
second imprinted locus (RB1, full data in Table S3) [41].
FGF6 (fibroblast growth factor 6)
Hepitypes located on the CpG island in the FGF6 gene and the
corresponding maximum-parsimony trees are depicted in Figure 6.
Figure 3. The Figure gives an overview of the amplicon and primer positions of the design, coverage and CpG methylation for the
hepityping region IRF4 (panel B, chromosome 6 from 352,937–366,151 bp). The location relative to the gene model, the primer positions,
the log10 coverage and the percentage of methylation for the two colorectal cancer samples are plotted as a function of the genomic coordinates.
doi:10.1371/journal.pone.0021332.g003
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tissue specimen (CRC-NT), the central CpGs of this locus are
demethylated in the matching colorectal tumor. The respective
hepitype 12 is only observed in the CRC-TU samples (25.5%
frequency). The follicular lymphoma shows a different demethyl-
ation pattern (hepitype 17), which nevertheless involves the same
region of the CpG island. Interestingly, the frequency of the
partially demethylated hepitype and the degree of demethylation
increases in the follicular lymphoma with disease progression in
comparison of FL-R1 to FL-R2. Three sites overlap between the
predominant demethylated hepitypes for the follicular lymphoma
and colon cancer sample (hepitypes 12 and 17 in Figure 4, sites
marked in bold print). The common telomeric demethylated
position (at 4,424,667 bp, left most T in bold print in hepitypes 12
and 17) overlaps with a TAF1 site. TAF1, a protein found at the
start of transcribed genes, is a general transcription factor that is a
key part of the pre-initiation complex found on the promoter and
might, thus, be involved in deregulation of the FGF6 growth
factor.
HS3ST2 (heparan sulfate 3-O-sulfotransferase 2)
The hepitype structure of HS3ST2 as depicted in Figure 7 shall
serve as an example of a locus that is being progressively
methylated in the tumor samples studied. As illustrated by the
maximum-parsimony trees, hepitype 37 (completely unmethy-
lated) is the dominant hepitype in the normal colon tissue (83.7%
abundance), with few randomly distributed single methylated
CpGs (e.g. hepitypes 31 to 35). In the tumor sample, a significant
proportion of sites are methylated. This process is most clearly
visible in the progression of the follicular lymphoma from FLR1-
to FL-R2. In the first biopsy, hepitype 37 (completely demethyl-
ated) is still the dominant hepitype, whereas in the second
recurrence, hepitype 1 (completely methylated) has increased in
frequency from 21.9% to 81.8%, corresponding to a ‘‘shift’’ from
left to right in the maximum-parsimony trees (Figure 7, panel B).
Discussion
We report the adoption of the recently described mircodroplet
PCR [32] to bisulfite treated target DNA and established a
pipeline for the simultaneous assessment of DNA sequence analysis
and methylation. We show that successful assessment of methyl-
ation status can be achieved for a wide range of target sequences,
with an average of 95% of target sequence (median 100%). In
principle, this approach is similar to a previously reported DNA
methylation profiling experiment on chromosomes 6, 20 and 22,
that also used PCR products from bisulfite converted DNA and
applied Sanger sequencing to the resulting products [29]. Here, we
utilize the advantages of microdroplet PCR and second-generation
sequencing technology. We used approximately 1000 primer pairs
to cover some 34 kb of genomic sequence – i.e. approximately one
primer every 34 bp with a 100% success rate (see Results). The
efficiency and scalability of the approach depends on the structure
of the genomic regions of interest. If large numbers of small sites
(e.g. well defined CpG islands) are studied, the design and
sequencing overhead of primer sequences is greater, whereas
Figure 4. Panel A depicts the correlation of the degree of
methylation as measured by pyrosequencing (y-axis, denoted
‘‘pyro’’) and by sequencing of the droplet-PCR products (x-
axis, denoted ‘‘454’’) for all 248 CpG loci studied with both
methods in the panel for all four samples. The Spearman rank
correlation coefficient is denoted in the Figure as ‘‘rho’’. Panels B and C
provide a pairwise correlation plot and analysis of the degree of
methylation for the forward and reverse strand for 25 CpG sites in the
IGF2 gene.
doi:10.1371/journal.pone.0021332.g004
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study) can be more efficiently covered. For instance, the total
sequence spanned by the amplicons including primers was
42455 bp in this study. The pipeline has a considerable scalability
potential, because the degree of redundancy may be reduced, the
proportion of longer amplicons might be increased and larger
numbers of primers (up to 4000 in the current RainDance tech-
nical specifications) may be incorporated in the libraries.
Figure 5. The figure shows the hepitypes of at the CpG island
at genomic coordinates on chromosome 15 (22,751,474–
22,751,613 bp) at the SNRPN (small nuclear ribonucleoprotein
polypeptide N) locus for the sample CRC-NT providing an
example of an imprinted gene. In panel A, the hepitype frequencies
and an overview of the locus structure is given. Panel B shows a
maximum-parsimony tree constructed from hepitypes with a minimum
frequency of 1%. The numbered hepitypes from panel A are annotated
in the tree. The frequent hepitypes are indicated by grey circles sized
according to the relative hepitype frequencies. Panel C summarizes the
frequency of methylated and non-methylated sites on the background
of the two hepitypes (left completely unmethylated – all T, right –
completely methylated – all C) defined by the imprinting of the locus.
As detailed in the Results section, single unmethylated sites occur more
frequently on the background of the all C hepitype, than single
methylated sites on the background of the unmethylated hepitype
(p,1610
215).
doi:10.1371/journal.pone.0021332.g005
Figure 6. Hepitype diversity at the FGF6 (fibroblast growth
factor 6) locus on chromosome 12 (4,424,623–4,424,748 bp) is
characterized by progressive demethylation in tumors. In panel
A, the hepitype frequencies in the four samples and an overview of the
locus structure is given. Panel B shows maximum-parsimony trees
constructed from hepitypes with a minimum frequency of 1%. The
numberedhepitypesfrompanelAareannotatedinthetrees.Thefrequent
hepitypes are indicated by grey circles sized according to the relative
frequencies. Trees have been constructed separately and branch lengths
arethusnottoscale.Itisevident,thatbothincomparisonbetweennormal
tissue and tumor in the colon cancer sample (CRC-NT, CRC-TU) and in
comparison between the follicular lymphoma and it’s recurrence (FL-R1,
FL-R2), the locus is characterized by progressive demethylation. The
consistently demethylated sites between the colon cancer and lymphoma
between hepitypes 12 and 17 are marked in bold print.
doi:10.1371/journal.pone.0021332.g006
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order to increase throughput and ease of methylation analysis
[26,27,28], this targeted approach may be useful, because it
allows a selective and thus economical use of sequencing
resources. Sequencing depth may be adjusted to achieve the
necessary precision for methylation and hepitype assessment. The
PCR-based approach also facilitates the alignment of the re-
sulting sequence reads, which may lead to ambiguous results in
whole-genome experiments due to the decreased complexity of
sequencing reads in bisulfite-treated target sequences. The fea-
sibility of measuring differential methylation over large regions,
for example, the peak regions of a susceptibility region for a
complex cancer such as colon cancer or lymphoma is demonstrated
in this report (Figure 3).
We assessed the validity of the methylation readings from our
pipeline approach with a set of 18 manually designed pyrose-
quencing assays analysing 248 CpG sites and found a good
concordance yielding a pairwise correlation coefficient of 0.87.
Interestingly, the reproducibility of strand readings was higher for
the sequencing reads (rho=0.96) as compared to the degree of
methylation as measured by pyrosequencing from both strands
(rho=0.88). Thus, the comparison to BS pyrosequencing as a
gold standard may be overly conservative towards the presented
pipeline approach.
We deliberately chose a sequencing technology that delivers
relatively long continuous stretches of sequence information, i.e.
the Roche FLX system. The average read length in this experi-
ment was 204 bases, allowing us to obtain phased methylation
information and the construction of ‘‘hepitypes’’. These hepitypes
provide the potential to study phylogenetic traces of somatic
evolution in cancer, such as recently demonstrated for SNP
variation by Campbell et. al. [23]. The potential of our pipeline in
the investigation of somatic methylation evolution is demonstrated
here for three exemplary loci: SNRPN (small nuclear ribonucleo-
protein polypeptide N), an example of an imprinted gene; FGF6
(fibroblast growth factor 6) demonstrating a locus with increasing
demethylation in cancer; and HS3ST2 (heparan sulfate 3-O-
sulfotransferase 2) exhibiting a pattern of locus methylation in
the progress of cancerogenesis. Due to the design as a proof-
of-principle experiment, biological conclusions that might be
drawn from this limited dataset must be viewed with considerable
caution. However, we demonstrate a consistent and statistically
significant skew in single base methylation and demethylation on
the background of the imprinted hepitypes at the SNRPN locus
towards incomplete methylation of the imprinted (methylated)
hepitype in all samples studied. This may be due to the active
nature of the methylation process. The progressive contextual
hepitype methylation and demethylation as seen in FGF6 and
HS3ST2 may provide a paradigm for further studies, especially if
different tumor entities with the same direction of overall methy-
lation change but a different hepitype pattern are analyzed. This
approach may allow an easier pinpointing of functionally relevant
sites of differential methylation as suggested in the hepitype
patterns at the FGF6 locus (Figure 6).
In summary, we present a novel approach for the targeted
assessment of differential methylation using microdroplet PCR
and second generation sequencing and show its utility for the
analysis of hepitype phylogeny in the somatic evolution in cancer.
Figure 7. Hepitype diversity at the HS3ST2 (heparan sulfate 3-
O-sulfotransferase 2) locus on chromosome 16 (22,733,111–
22,733,201 bp) is characterized by increasing methylation in
tumor samples. In panel A, the hepitype frequencies in the four
samples and an overview of the locus structure is given. Panel B shows
maximum-parsimony trees constructed from hepitypes with a mini-
mum frequency of 1%. The numbered hepitypes from panel A are
annotated in the trees. The frequent hepitypes are indicated by grey
circles sized according to the relative frequencies. Trees have been
constructed separately and branch lengths are thus not to scale. It is
evident, that both in comparison between normal tissue and tumor in
the colon cancer sample (CRC-NT, CRC-TU) and in comparison between
the follicular lymphoma and it’s recurrence (FL-R1, FL-R2), the locus is
characterized by progressive methylation yielding for instance an 82%
frequency of the completely methylated hepitype in the recurrent
lymphoma (FL-R2).
doi:10.1371/journal.pone.0021332.g007
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Figure S1 Verification of successful bisulfite conversion:
The figure shows the pyrosequencing trace of the sample
CRC-TU at the SMAD7 locus (chromosome 18, position
46,448,939–46,448,969). The same converted sample, which
was used for the sequencing and an analysis pipeline presented in
the manuscript, was analysed with bisulfite pyrosencing. For the
internal bisulfite control position a ‘‘c’’ is injected before and after
the converted ‘‘t‘‘. No light signals were obtained for these positions
demonstrating complete and successful bisulfite conversion.
(TIF)
Figure S2 The figure provides the rationale for choosing
95% sequence identity as a criterion for the selection of
converted amplicon reads in the analysis. The dashed line
shows the frequency of reads with the identity to the predicted
amplicon sequence on the x-axis. The 95% criterion that is custo-
mary for unconverted SNP discovery experiments thus appears to
be suitable for the converted amplicons as shown in the solid lines.
(TIF)
Table S1 Overview analysed regions. For some of the
smaller regions only manual design using previously designed or
only automatic design was attempted. Regions, where the
respective design method was not used are indicated by ‘‘n/a’’.
The large hepityping regions were only processed through the
automated pipeline. The coordinates are given according to NCBI
build 36.1 (UCSC hg18). The empirical coverage by sequencing
reads exactly corresponds to the theoretically expected one and is
thus not provided separately.
(XLS)
Table S2 List of all primer pairs and amplicon yield in
the experiment: The primer sequences and target genes
are provided. The mean number of aligned finished reads for
each amplicon normalized on 100,000 reads over all four libraries
is provided in the column ‘‘normalized mean’’ in addition to the
raw sequence counts per amplicon and the normalized (on
100,000 reads per library) reads for each of the four samples.
(XLS)
Table S3 The table provides a list of all methylated
sites in the analyzed samples. Genomic coordinates refer to
NCBI build 36.1 (UCSC hg18). CpG sites that are generated
through a SNP are marked in underlined italics. Sites covered by
less than 20 reads are marked in non-underlined italics. Sites with
no reads in the respective sample are indicated with a dash (‘‘-’’).
Sites without a CpG in a particular sample are marked with
‘‘NA’’. The percentage of methylation is given for each site.
(XLS)
Table S4 List of all polymorphic sites (SNVs and
InDels) in the individual samples. The chromosome,
chromosomal position, alleles and individual genotypes are
provided for all samples.
(XLS)
Table S5 The table provides an overview of the 18
manually designed pyrosequencing assays for the rep-
lication of the measurement of DNA methylation at 17
selected loci. Note, that for the IGF2 locus, an assay on the
forward and the reverse strand has been designed.
(XLS)
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